Advisory Board
Four pillars determine a platform's ceiling.
Scientific capability, industry experience, and capital acumen — they only deliver outcomes when they coexist. NAPPA's advisory structure is built around the four dimensions cross-border execution actually requires.
Inaugural advisors
Across Science, Drug R&D, Industry Translation, and Capital.
XZ
Science
Xumu Zhang
Professor; Dean, Medi-X Institute
Southern University of Science and Technology (SUSTech)
Distinguished scientist in asymmetric catalysis with 400+ publications,
25,000+ citations, and 50+ international patents. Previously held
professorships at Pennsylvania State University and Rutgers. BS, Wuhan
University; PhD in Chemistry, Stanford.
MF
Drug R&D
Mann Fung, MD
Former CEO, Tavotek Biotherapeutics
Pharma leadership across J&J (where he helped develop the BTK inhibitor
Ibrutinib) and senior oncology roles at Eli Lilly. MD, University of Utah;
MHCM, Harvard.
QL
Industry Translation
Qin Chao Lu
Founding Partner & Chairperson, Danlu Capital
Healthcare investment veteran managing approximately 2 billion RMB. Former
Partner at Sequoia Capital China for 13 years and one of Sequoia's first
female global partners. Tongji Medical College; MBA, Chinese University
of Hong Kong.
XH
Capital
Xin Sylvia He, PhD
Managing Partner, Hyfinity Investments
Bridges global innovation with China's clinical resources. Former Senior
Partner at CDH Investments; previously founded and led a biopharmaceutical
company spanning China and U.S. operations. PhD in Immunobiology, Yale;
Princeton and USTC alumna.
Strategic advisors
Org-level strategic counsel.
Strategic advisors guide NAPPA's portfolio prioritization, cross-regional decision frameworks, and global R&D allocation — operating one level above any individual project.
JW
Joy Wang, PhD, MBA
Strategic Advisor
20+ years in global biopharma leadership across Novartis/Sandoz, Eli Lilly,
Baxter, and Dendreon. Expertise in portfolio strategy and Go/No-go decision
architecture, with therapeutic depth in neuroscience, oncology, and cell &
gene therapy.
Scientific advisors
Project-level scientific review.
Scientific advisors complement the four-pillar Advisory Board by providing focused, project-level scientific review for NAPPA-supported partnerships and out-licensing opportunities.
HZ
Hongwen Zhu, PhD
Scientific Advisor
PhD in Neuroscience, Chief Physician, and Doctoral Supervisor. Specially
Invited Researcher at New York Medical College; formerly VP & CTO of JD
Health and Vice President of Tianjin Hospital. Research background at Albert
Einstein College of Medicine and Columbia, with 100+ SCI publications focused
on neurological diseases and regenerative medicine.
YC
Yu Cao
Scientific Advisor
Detailed bio coming soon. For inquiries about engaging on a specific
project, please contact us.
JL
Junfang Li
Scientific Advisor
Detailed bio coming soon. For inquiries about engaging on a specific
project, please contact us.